Koch Institute for Integrative Cancer Research at MIT.

What Koch Institute for Integrative Cancer Research at MIT. does

The Koch Institute for Integrative Cancer Research at MIT is a National Cancer Institute-designated basic cancer research center and an organized research unit of the Massachusetts Institute of Technology, located at 500 Main Street, Building 76 in Cambridge, Massachusetts. The institute operates a convergence science model that integrates biology and engineering to address cancer detection, diagnosis, treatment, and management. Research is organized along three NCI-defined scientific programs: Genetic and Cellular Programs in Cancer; Cancer Biology and Immunology; and Systems and Engineering Approaches to Cancer. The Koch Institute's underlying technology stack includes proprietary single-cell analysis platforms (Suspended Microchannel Resonator for measuring buoyant mass and stiffness), CRISPR/prime editing tools for in vivo cancer driver interrogation, microfluidic circulating tumor cell sorting platforms, nanoparticle-based drug delivery systems, and an expanding suite of AI/ML tools for peptide design, cancer risk prediction, and tumor evolution modeling.

The institute generates revenue through a diversified funding model rather than commercial sales, receiving support from the NCI Cancer Center Support Grant (P30-CA014051), individual investigator grants from NIH and other agencies, foundation support, philanthropy, and industry collaborations. Established in its current form in 2007 through a $100 million gift from David H. Koch (building on MIT's NCI cancer center designation dating to 1974), the Koch Institute serves academic and clinical cancer researchers as its primary audience, biotechnology and pharmaceutical companies through the BioConvergence Cancer Alliance, and graduate students and postdoctoral researchers through training programs. The institute accelerates bench-to-bedside translation via the Bridge Project with Dana-Farber/Harvard Cancer Center, the Frontier Research Program, clinical collaborations with Dana-Farber and Massachusetts General Hospital, and a documented pipeline of faculty spinout companies that have generated technologies licensed to over 400 organizations globally. The institute also operates the Swanson Biotechnology Center (SBC) Core Facilities, providing shared research infrastructure across 10 cores including flow cytometry, high throughput sciences, nanotechnology for integrative bioEM, preclinical modeling and imaging, and data science and multimodal integration.

Name

Koch Institute for Integrative Cancer Research at MIT.

Legal name

Koch Institute for Integrative Cancer Research at MIT

Website

https://ki.mit.edu

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

51–100 employees

Short description

The Koch Institute for Integrative Cancer Research at MIT is an NCI-designated basic cancer research center that applies convergence science, integrating biology and engineering to develop cancer detection, diagnostic, and treatment technologies for academic researchers, industry partners, and clinical collaborators.

Ownership category

akta.pro rank

Product category

Academic Cancer Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI)

akta.pro secondary industries

Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE), Transcriptomics & Gene Expression Profiling Services (HLAGANAE)

Keywords

• Cancer research
• Biomedical engineering
• Translational medicine
• Immunotherapy research
• Nanomedicine development

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Research Grants and Funding: The institute receives substantial funding through NCI Cancer Center Support Grant (P30-CA014051), individual investigator grants from NIH and other agencies, foundation support, and industry collaborations. Funding supports core research facilities, training programs, and selected staff members.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

The Koch Institute for Integrative Cancer Research at MIT is a National Cancer Institute-designated basic cancer research center that performs discovery and translational cancer research across three program themes. It provides shared research infrastructure through the Swanson Biotechnology Center (SBC) Core Facilities (flow cytometry, genomics, cryoEM, preclinical imaging, spatial imaging, zebrafish, histology, data science) and operates dedicated centers such as the Marble Center for Cancer Nanomedicine and the MIT Center for Precision Cancer Medicine. The institute trains graduate students and postdoctoral researchers, runs industry-academia engagement through the BioConvergence Cancer Alliance, and licenses foundational research tools and therapeutics to spinout companies.

Product overview

The Koch Institute for Integrative Cancer Research at MIT is a National Cancer Institute-designated basic cancer research center organized around three scientific program themes (Genetic & Cellular Programs, Cancer Biology & Immunology, and Systems & Engineering Approaches) and operates the Swanson Biotechnology Center (SBC) providing shared research core facilities. The institute does not offer commercial products but provides research services through its core facilities including Flow Cytometry, High Throughput Sciences, Integrated Genome Technologies, Nanotechnology for Integrative BioEM (cryoEM), Preclinical Modeling, Preclinical Imaging & Testing, Tissue Processing, Spatial Imaging, Zebrafish, and Data Science & Multimodal Integration. Research centers include the Marble Center for Cancer Nanomedicine and MIT Center for Precision Cancer Medicine. Key research technologies include CleaveNet AI peptide design, suspended microchannel resonator for single-cell analysis, nanoparticle immunotherapy platforms, and CRISPR-based genome editing models.

Differentiator

Problem solved

Functional benefit

Brands

• BioConvergence Cancer Alliance: An alliance fostering relationships between academic cancer researchers and biotechnology companies to accelerate translation of discoveries into treatments
• SBC Core Facilities
• Program 1: Genetic & Cellular Programs in Cancer
• Program 2: Cancer Biology & Immunology
• Program 3: Systems & Engineering Approaches to Cancer
• Bridge Project
• Marble Center for Cancer Nanomedicine
• MIT Center for Precision Cancer Medicine

Products and services

• SBC Core Facilities (Swanson Biotechnology Center) Shared research core facilities offering access to specialized equipment and services including Flow Cytometry, High Throughput Sciences, Integrated Genome Technologies, Nanotechnology for Integrative BioEM (cryoEM and CLEM), Preclinical Modeling, Preclinical Imaging & Testing, Tissue Processing/Hope Babette Tang (1983) Histology Facility, Spatial Imaging, Zebrafish, and Data Science & Multimodal Integration for internal and external cancer researchers.
• Suspended Microchannel Resonator (SMR) Single-Cell Analysis Platform Microfluidic instrumentation that weighs single cells with precision, measuring biophysical properties such as buoyant mass and stiffness at the single-cell level for cancer research and precision medicine applications, including real-time detection and extraction of rare circulating tumor cells from live mouse models.
• CleaveNet AI Peptide Design System AI system developed by the Bhatia Lab to design peptides cleaved by cancer-associated proteases, integrated into nanosensors for early tumor detection via simple urine tests.
• Marble Center for Cancer Nanomedicine Research center directed by Sangeeta Bhatia dedicated to using tiny technologies to make big advances for patients in cancer detection and treatment, supporting nanosensor development, human microliver models, and related nanotechnology research.
• MIT Center for Precision Cancer Medicine Research center directed by Michael Yaffe focused on systems pharmacology and determining how to target cross-talk between pathways with specific drug combinations to increase cancer treatment efficacy, including the development of the Kinase Atlas resource for precision cancer medicine.
• Bridge Project (MIT–Dana-Farber/Harvard Cancer Center) Translation collaboration between MIT's Koch Institute and Dana-Farber/Harvard Cancer Center that addresses major challenges in cancer through joint bench-to-bedside research projects drawing on both institutions' complementary strengths.
• Frontier Research Program Flagship translational initiative of the Koch Institute's bench-to-bedside pipeline that advances high-potential cancer research from the lab toward clinical and commercial application.
• BioConvergence Cancer Alliance Industry partnership program fostering relationships between Koch Institute academic cancer researchers and biotechnology and pharmaceutical companies (including founding member Astellas Pharma) to accelerate translation of discoveries into clinical applications and provide sponsored research access.
• CRISPR/Cas9 Intestinal Cancer Organoid Models and Endoscopic Mucosal Gene Editing Preclinical cancer modeling tools developed by the Yilmaz Lab providing genome-edited intestinal cancer organoids and mucosal-directed CRISPR/Cas9 genome editing methods for studying tissue regeneration, aging, and cancer initiation.
• Tumor Phosphoproteomics Analysis Platform (White Lab) Analysis platform using tumor phosphoproteomics to identify why tyrosine kinase inhibitors fail in some patients and to guide combination therapy decisions by mapping backup signaling networks that confer resistance.
• Cancer Research Training and Fellowship Programs Training and fellowship programs that produce the next generation of leading cancer investigators through postdoctoral and graduate research opportunities, research forums, seminars, and access to state-of-the-art equipment.

Quantifiable outcome

• Robert Langer's work generated tens of companies, licensing to over 400 organizations globally
• +1 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature6 records

Partnerships

21 partnerships are on record, tiered core and minor.

• Research Institute, National Cancer Center JapancoreStrategic or Co-development Partner · 1 June 2026Strategic collaboration via Memorandum of Understanding to leverage both parties' excellence in research to solve pressing problems in cancer and shape convergence science in oncology in areas including immune-oncology, basic and epidemiologic cancer research, prevention, diagnosis, and treatment.
• Astellas PharmacoreStrategic or Co-development Partner · 15 May 2026Astellas Pharma joined the BioConvergence Cancer Alliance to engage with Koch Institute research community and flagship initiatives including Frontier Research Program. Inaugural meeting identified alignment in immuno-oncology, targeted protein degradation, drug delivery, and AI.
• Break Through CancercoreStrategic or Co-development Partner · 11 December 2025Multi-site clinical trial led by Break Through Cancer targeting CD123 to eliminate residual leukemia cells in AML patients. Combines targeted therapy with existing treatments and uses advanced biological assays to improve detection and eradication of MRD.
• Ludwig Center at MITcoreStrategic or Co-development PartnerCollaborative research center supporting cancer research programs including work by Manalis, Bhatia, and others. Provides fellowship funding and supports research initiatives.
• Marble Center for Cancer NanomedicinecoreStrategic or Co-development PartnerDedicated to using tiny technologies to make big advances for patients in cancer detection and treatment. Celebrated 10-year anniversary in 2026 with symposium gathering faculty, alumni, and industry collaborators.
• MIT Center for Precision Cancer MedicinecoreStrategic or Co-development PartnerCenter focused on systems pharmacology and determining how to target cross-talk between pathways with specific drug combinations. Directed by Michael Yaffe, with members including Scott Manalis.
• Broad Institute of MIT and HarvardcoreStrategic or Co-development PartnerMany Koch Institute faculty hold joint appointments at the Broad Institute. Collaborative research including cancer dependency map, single-cell analysis, and genome editing projects.
• TraveraminorOEM/ Whitelabel/ Licensing PartnerCompany founded by Scott Manalis utilizing suspended microchannel resonator technology for weighing single cells in cancer diagnostics and treatment prediction.
• Affinity BiosensorsminorOEM/ Whitelabel/ Licensing PartnerCompany founded by Scott Manalis utilizing suspended microchannel resonator technology for single cell analysis applications.
• Ankyra TherapeuticsminorOEM/ Whitelabel/ Licensing PartnerCompany utilizing techniques from Wittrup and Irvine labs to keep interleukin-12 anchored in tumors, enhancing immune response while reducing side effects.
• Consensus PharmaceuticalsminorOEM/ Whitelabel/ Licensing PartnerCo-founded by Michael Yaffe for development of targeted cancer therapeutics based on signaling pathway research.
• Merrimack PharmaceuticalsminorOEM/ Whitelabel/ Licensing PartnerCo-founded by Michael Yaffe for development of targeted cancer therapies based on systems pharmacology approaches.
• Kelonia TherapeuticsminorOEM/ Whitelabel/ Licensing PartnerSpinout from Michael Birnbaum lab developing in vivo gene editing platform including single-infusion CAR-T cancer therapy. Being acquired by Eli Lilly.
• Kronos BiominorOEM/ Whitelabel/ Licensing PartnerBiotechnology company founded by Angela Koehler focused on targeting transcription factors in cancer.
• 76BiominorOEM/ Whitelabel/ Licensing PartnerBiotechnology company founded by Angela Koehler based on chemical biology approaches.
• Ligon DiscoveryminorOEM/ Whitelabel/ Licensing PartnerBiotechnology company founded by Angela Koehler for small molecule discovery tools.
• Samori BiominorOEM/ Whitelabel/ Licensing PartnerBiotechnology company founded by Angela Koehler.
• Danger BiominorOEM/ Whitelabel/ Licensing PartnerCo-founded by Stefani Spranger for immunotherapy development.
• CisionVisionminorOEM/ Whitelabel/ Licensing PartnerCo-founded by Angela Belcher and former trainee Jeremy Li, received up to $22 million ARPA-H funding for Precision Surgical Interventions.
• Dana-Farber Cancer InstitutecoreStrategic or Co-development PartnerClinical collaborator in cancer research including work with Manalis, Vander Heiden, and other faculty. Joint research programs and clinical translations.
• Massachusetts General HospitalcoreStrategic or Co-development PartnerClinical collaborator including Yilmaz who is a gastrointestinal pathologist at MGH, and other joint research initiatives.

Scale indicators3 records

Recent moves10 records

Expansion highlights5 records

Direct peers

• Johns Hopkins Sidney Kimmel Cancer Center: NCI-designated comprehensive cancer center with deep basic research programs in cancer biology and immunology plus extensive clinical translation, comparable in academic breadth and research output to Koch Institute's programs.
• Dana-Farber Cancer Institute: Harvard-affiliated NCI-designated comprehensive cancer center with overlapping faculty, joint research programs with Koch (Bridge Project with MIT/Dana-Farber/Harvard Cancer Center), and shared clinical investigators such as Matthew Vander Heiden who practices at Dana-Farber. Strongest direct peer in terms of translational research pipeline.
• Fred Hutchinson Cancer Center: NCI-designated comprehensive cancer center with strong basic and translational research programs in cancer biology, immunology, and immunotherapy, plus major faculty spinouts in biotech. Comparable scientific scope to Koch Institute with similar academic-medical model.
• Cold Spring Harbor Laboratory: Academic research institution with cancer biology programs and NCI-designated cancer center, comparable mission of basic cancer research and training of next-generation scientists. Notable overlap in faculty connections (Koch's Michael Hemann post-doc'd at CSHL with Scott Lowe).
• UCSF Helen Diller Family Comprehensive Cancer Center: NCI-designated comprehensive cancer center with strong programs in computational biology, immuno-oncology, and precision medicine, comparable in academic translational research scope to Koch Institute's programs.
• Stanford Cancer Institute: NCI-designated comprehensive cancer center with strong engineering-medicine convergence programs, AI/ML for oncology, and biotech spinouts, comparable in academic culture and engineering-biology integration to Koch Institute's model.
• Broad Institute of MIT and Harvard: Many Koch Institute faculty hold joint appointments at the Broad Institute, including joint programs in cancer dependency mapping, single-cell analysis, and genome editing. Direct peer in genomic and computational cancer research, with overlapping PIs and shared core capabilities.
• Wistar Institute: One of the oldest NCI-designated basic cancer research centers focused exclusively on bench science without clinical operations, structurally similar to Koch Institute's NCI designation as a basic cancer research center. Closest structural analogue in the NCI center ecosystem.

Broad incumbents

• Memorial Sloan Kettering Cancer Center: One of the world's largest and oldest NCI-designated comprehensive cancer centers, with deep basic and translational research programs, clinical trials, and industry partnerships broadly overlapping with the Koch Institute's cancer research mandate. Far larger clinical operation but similar mission of advancing cancer science.
• MD Anderson Cancer Center: The largest NCI-designated comprehensive cancer center globally, with a massive research enterprise spanning basic, translational, and clinical oncology broadly comparable to Koch Institute's mission but at significantly greater scale and patient volume.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks2 records

Key highlights1 record

Customer concentration

• Xx.com/kochinstitute
• Facebookfacebook.com/kochinstitute
• LinkedInlinkedin.com/company/mit-koch-institute-for-integrative-cancer-research
• Instagraminstagram.com/kochinstitutemit

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Koch Institute for Integrative Cancer Research at MIT.